Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  246.47
-0.91 (-0.37%)
AAPL  260.25
+0.88 (0.34%)
AMD  207.69
+4.52 (2.22%)
BAC  55.19
-0.66 (-1.18%)
GOOG  332.73
+3.59 (1.09%)
META  641.97
-11.09 (-1.70%)
MSFT  477.17
-2.11 (-0.44%)
NVDA  184.94
+0.08 (0.04%)
ORCL  204.68
+6.16 (3.10%)
TSLA  448.96
+3.95 (0.89%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.